… and older, vaccination coverage with PPV23 is estimated to be low (1). This study aimed
to assess the cost-effectiveness of vaccinating elderly in a national vaccination programme in …

… A 2018 analysis found, in pneumococcal vaccine–naive … pneumococcal vaccination in
seniors, including this analysis, were presented, with cost-effectiveness estimates of both vaccines …

… Pneumococcal disease, which presents a substantial health and economic burden, is
prevented through pneumococcal vaccination programs. We assessed the impact of switching …

… cost-effectiveness of pneumococcal vaccination strategies – including PCV20 alone and
others – relative to PPV23 alone (single dose). Our findings suggest replacing PPV23 with …

… This study compared the cost-effectiveness of pneumococcal vaccines applied in … of vaccine
price decreases on cost-effectiveness. We reviewed the pricing of pneumococcal vaccines …

… In this decision model-based cost-effectiveness analysis, we compare the newly
recommended US pneumococcal vaccination options among medically underserved and non-…

… pneumococcal vaccine choices are in the Hong Kong healthcare environment. We aimed to
assess the cost-effectiveness … of PPSV23 vaccination for pneumococcal disease control in …

… pertaining to the cost-effectiveness of pneumococcal vaccines in older adult … Cost-effectiveness
Analysis (CEA) Registry. To capture some of the earliest economic research on vaccine …

… Two novel pneumococcal vaccines, PCV15 and PCV20, are expected to be … a cost-effectiveness
analyses examining the value for money of replacing the current PPSV23 immunisation …

… pneumococcal disease (PD) aged ≥ 6 years. The aim of this study was to assess the cost-effectiveness
of the new vaccines, … the lifetime cost-effectiveness of vaccination with PCV15 + …